Trial Search Results

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumors

The purpose of this study is to assess the median progression-free survival (PFS)of patients with well differentiated, metastatic and/or unresectable typical or atypical lung neuroendocrine tumors treated with Lanreotide Autogel/Depot plus BSC versus placebo plus BSC.

Stanford is currently not accepting patients for this trial.

Stanford Investigator(s):

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting